Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF and Ipilimumab in Metastatic Melanoma
NCT01363206Phase 2Completed
- Start
- May 2011
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim, ipilimumab in melanoma. Started May 2011; status: completed.
02
Drugs
sargramostimipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01363206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363206.